The CCR2 inhibitor CCX-872 was shown to attenuate the infiltration of CD11b+CD11c+F4/80+ monocytes into the liver, thus improving glycemic control and liver inflammation, injury and fibrosis in a murine NAFLD model (high-fat/high-fructose diet). Here, CCR2 is linked to metabolic dysfunction-associated steatotic liver disease.